IMAAGEN Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on PSA in Patients with Non-Metastatic Castration-Resistant Prostate Cancer - Charles Ryan

Charles Ryan presents an update to the IMAAGEN Trial which includes the percentage of patients with event-free rates for PSA progression at 12, 18, and 24 months and radiographic evidence of disease progression with non-metastatic castration-resistant prostate cancer when taking abiraterone acetate and low dose predisone.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe